Ultimately, we envision our competition as the disease rather than other companies
In Conversation
One advantage of being a family-owned rather than a stock market driven company is that we do not only focus on fashionable segments like oncology, but…
This is a very exciting moment for the Santen US affiliate
BMS Norway is absolutely going to be one of Norway’s largest companies in terms of value
The biggest challenge for us is that while responding to the immediate crisis caused by the global pandemic, we still needed to continue and coordinate our…
Why should Switzerland import a system that has patently been shown to be wrong-headed elsewhere and that will trigger drug shortages?
We are happy and proud to be pioneers in neuroscience, but our pioneering work also requires us to keep pace with an increasingly ambiguous and changing…
With rare disease patients and families deeply affected by COVID-19, important policy issues at a critical point and scientific innovation advancing more rapidly than at any…
It will take some time but if the industry is able to continue to produce talent, new technology and solutions, diagnostic tools, and treatments, gradually the…
PPPs are not for everyone nor for everything – but for certain topics, they are the only way to make progress and tackle some huge challenges
Across research, development, and commercialization, our team is focused on advancing innovations that can address unmet needs, and we expect to see huge growth despite the…
Switzerland is very open to innovative products, and for a company like Janssen, which is focused on innovative, high-value products, we see good and strong uptake…
